Lee R G, Tsamandas A C, Demetris A J
Department of Pathology, University of Pittsburgh Medical Center, PA, USA.
Hepatology. 1997 Dec;26(6):1415-22. doi: 10.1002/hep.510260607.
Large cell change (LCC), characterized by cellular enlargement, nuclear pleomorphism and hyperchromasia, and multinucleation of hepatocytes, is a common lesion in cirrhotic livers, but its nature, significance, and pathogenesis remain uncertain. Therefore, we assessed the prognostic value of LCC as a marker of subsequent hepatocellular carcinoma (HCC) through a case-control study that compared pretransplant liver biopsy specimens from 37 cirrhotic liver transplant recipients with HCC to specimens from a control group of recipients without HCC, matched for sex, age (+/-5 years), and cause of cirrhosis. LCC was identified in 16 (43%) of the study and 7 (19%) of the control group biopsy specimens. By matched-pair analysis, LCC conveyed a moderately increased risk of later HCC with an estimated odds ratio of 3.3 (95% CI, 1.2-15; P = .038). However, a pathology review of 45 HCCs showed adjoining LCC in only 12 (27%) and did not suggest a morphological transition or a histogenetic association between the two lesions. LCC hepatocytes displayed a low proliferative rate by Ki-67 or proliferating cell nuclear antigen immunostaining (labeling indices of 0.27 and 0.73) but showed a greater degree of apoptosis than normal hepatocytes (labeling indices of 1.9 and 0.23; P = .03) To reconcile these findings, we propose that LCC derives from derangements in the hepatocyte's normal process of polyploidization. Such derangements, possibly caused by chronic inflammation-induced DNA damage, could yield a population of enlarged liver cells with nuclear atypia and pleomorphism, frequent binuclearity, and minimal proliferation. According to this hypothesis, LCC would be a habitual feature of cirrhosis and a regular accompaniment of HCC but would not represent a direct malignant precursor.
大细胞改变(LCC)的特征为细胞增大、核多形性和深染以及肝细胞多核化,是肝硬化肝脏中的常见病变,但其性质、意义和发病机制仍不明确。因此,我们通过一项病例对照研究评估了LCC作为后续肝细胞癌(HCC)标志物的预后价值,该研究比较了37例患有HCC的肝硬化肝移植受者的移植前肝活检标本与未患HCC的对照组受者的标本,对照组受者在性别、年龄(±5岁)和肝硬化病因方面相匹配。在研究组的16份(43%)活检标本和对照组的7份(19%)活检标本中发现了LCC。通过配对分析,LCC使后期发生HCC的风险适度增加,估计比值比为3.3(95%CI,1.2 - 15;P = 0.038)。然而,对45例HCC进行的病理检查显示,仅12例(27%)有相邻的LCC,且未提示这两种病变之间存在形态学转变或组织发生学关联。通过Ki - 67或增殖细胞核抗原免疫染色,LCC肝细胞显示出低增殖率(标记指数分别为0.27和0.73),但与正常肝细胞相比显示出更高程度的凋亡(标记指数分别为1.9和0.23;P = 0.03)。为了协调这些发现,我们提出LCC源自肝细胞正常多倍体化过程中的紊乱。这种紊乱可能由慢性炎症诱导的DNA损伤引起,可产生一群具有核异型性和多形性、频繁双核化且增殖极少的增大肝细胞。根据这一假设,LCC将是肝硬化的常见特征和HCC的常见伴随病变,但不代表直接的恶性前体。